| Literature DB >> 35625533 |
Maciej Idzik1, Jakub Poloczek2,3, Bronisława Skrzep-Poloczek4, Ewelina Dróżdż5, Elżbieta Chełmecka5, Zenon Czuba6, Jerzy Jochem4, Dominika Stygar4.
Abstract
Rehabilitation in osteoarthritis (OA) patients aims to reduce joint pain and stiffness, preserve or improve joint mobility, and improve patients' quality of life. This study evaluated the effects of the 21-day individually adjusted general rehabilitation program in 36 OA patients 90 days after hip or knee replacement on selected interleukins (IL) and cytokines using the Bio-Plex® Luminex® system. Serum concentrations of almost all selected anti/pro-inflammatory markers: IL-1 receptor antagonist (IL-1RA), IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, IL-15, and of some chemokines: macrophage inflammatory protein-1 alpha (MIP-1α/CCL3), and RANTES/CCL5, and of eotaxin-1/CCL11, the vascular endothelial growth factor (VEGF) significantly increased, whereas basic fibroblast growth factor (FGF basic) significantly decreased after the 21-day general rehabilitation. The levels of interferon-γ induced protein 10 (IP-10), MIP-1β/CCL4, macrophage/monocyte chemoattractant protein-1 (MCP-1/CCL2 (MCAF)), granulocyte macrophage-colony stimulating factor (GM-CSF), platelet-derived growth factor-BB (PDGF-BB), and granulocyte colony-stimulating factor (G-CSF) remained unchanged. There were no changes in pro-inflammatory cytokines levels: tumor necrosis factor-alpha (TNF-α), interferon-γ (IFN-γ), and IL-12 (p70)) after the 21-day general rehabilitation, indicating the stable and controlled inflammatory status of osteoarthritis patients. Significantly higher levels of anti-inflammatory factors after 21 days of moderate physical activity confirm the beneficial outcome of the applied therapy. The increased level of IL-6 after the rehabilitation may reflect its anti-inflammatory effect in osteoarthritis patients.Entities:
Keywords: chemokines; cytokines; general rehabilitation; hip or knee implantation surgery; interleukins; osteoarthritis
Mesh:
Substances:
Year: 2022 PMID: 35625533 PMCID: PMC9139046 DOI: 10.3390/biom12050605
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
The levels of interleukins and cytokines in the serum of patients after hip or knee replacement in the course of osteoarthritis before and after the 21-day general rehabilitation program.
| Parameter [pg/mL] | Before Rehabilitation | After Rehabilitation | t/z * |
|
|---|---|---|---|---|
| IL-1β | 1.49 ± 1.62 | 1.59 ± 1.44 | 1.31 | 0.199 |
| IL-12 (p70) | 3.04 ± 1.61 | 3.27 ± 1.69 | 0.66 | 0.515 |
| IFN-γ | 2.20 ± 1.15 | 1.92 ± 1.11 | 1.32 | 0.197 |
| TNF-α | 13.47 ± 5.95 | 14.88 ± 6.16 | 1.90 | 0.067 |
| IL-2 | 3.78 (2.47;4.78) | 4.21 (2.53;5.23) | 3.84 * | <0.001 |
| IL-6 | 1.28 ± 0.80 | 1.64 ± 0.86 | 3.10 | <0.01 |
| IL-1RA | 121.51 ± 64.60 | 133.27 ± 61.21 | 2.09 | <0.05 |
| Il-4 | 2.65 ± 1.04 | 3.49 ± 1.31 | 3.97 | <0.001 |
| IL-10 | 1.89 ± 1.16 | 2.34 ± 1.16 | 4.92 | <0.001 |
| IL-13 | 5.60 ± 2.21 | 6.64 ± 2.68 | 2.27 | <0.05 |
| IL-15 | 110.86 ± 32.88 | 133.25 ± 29.71 | 3.48 | <0.01 |
| IL-5 | 10.32 (7.90;15.13) | 11.5 (10.11;17.79) | 2.52 * | <0.05 |
| IL-8/GRO | 9.13 (7.85;14.27) | 9.98 (6.11;12.01) | 1.61 * | 0.106 |
| GM-CSF | 3.27 (2.73;5.09) | 3.54 (2.23;5.60) | 0.20 * | 0.936 |
| MCP-1 (MCAF/CCL2) | 30.72 ± 14.06 | 33.00 ± 13.23 | 0.83 | 0.412 |
| MIP-1α/CCL3 | 2.37 ± 0.91 | 2.72 ± 1.36 | 2.21 | <0.05 |
| MIP-1β/CCL4 | 61.83 ± 27.73 | 57.27 ± 30.28 | 1.26 | 0.216 |
| RANTES/CCL5 | 4893.73 ± 1306.61 | 5643.70 ± 1617.48 | 3.53 | <0.01 |
| IL-7 | 6.93 ± 3.95 | 6.99 ± 3.94 | 0.07 | 0.944 |
| IL-9 | 50.75 ± 18.89 | 44.29 ± 24.26 | 1.48 | 0.150 |
| IL-17A | 10.36 ± 3.92 | 11.02 ± 4.59 | 0.89 | 0.381 |
| eotaxin-1/CCL11 | 112.53 ± 50.03 | 153.33 ± 53.83 | 6.21 | <0.001 |
| FGF basic | 24.80 ± 11.99 | 21.77 ± 8.98 | 2.66 | <0.05 |
| G-CSF | 24.28 ± 14.61 | 31.04 ± 19.89 | 1.34 | 0.189 |
| IP-10/CXCL-10 | 955.07 ± 438.41 | 956.14 ± 389.37 | 0.02 | 0.987 |
| PDGF-BB | 1726.01 ± 1691.87 | 1817.52 ± 1536.96 | 0.97 | 0.341 |
| VEGF | 93.16 ± 44.54 | 125.80 ± 61.33 | 4.01 | <0.001 |
Legend: FGF basic—basic fibroblast growth factor, G-CSF—granulocyte colony-stimulating factor, GM-CSF—granulocyte-macrophage colony-stimulating factor, GRO—growth-related oncogene, IFN-γ—interferon γ, IL—interleukin, IL-1RA—interleukin-1 receptor antagonist, IP-10/CXCL-10—interferon-γ induced protein 10, MCP-1, MCAF/CCL2 macrophage/monocyte chemoattractant protein-1, MIP-1α/CCL3—macrophage inflammatory protein-1 alpha, MIP-1β/CCL4—macrophage inflammatory protein-1 beta, PDGF-BB—platelet-derived growth factor-BB, TNF-α—tumor necrosis factor-alpha, and VEGF—vascular endothelial growth factor; *—Wicoxon’s test.